Keyword: Keytruda

Opdivo goes directly to the lucrative lung cancer market with its first nod in China, where nearly 800,000 new patients are diagnosed each year.

Another day, another approval for Merck immuno-oncology star Keytruda.

Merck’s Keytruda has a new indication, and with it, cancer immunotherapy has moved into a new frontier.

After making headlines at this year’s American Society of Clinical Oncology annual meeting, Merck’s Keytruda had a big week on the other side of the pond, too.

Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.

Many ASCO-watchers crowned Merck's Keytruda as king of the lung cancer market, but rivals Roche and BMS are kicking back.

Just how big has the wave of new cancer drug ads been? Syneos analyzed DTC data from the past decade to find out.

Merck spent on-stage ASCO time with new Keytruda data, but behind the scenes, it huddled with teams from its big new partners, AstraZeneca and Eisai.

Merck’s Keytruda has a solo OK for first-line lung cancer patients whose tumors bear high levels of PD-L1. But that group will likely soon get bigger.

At this year's ASCO, squamous lung cancer has elbowed nonsquamous disease off center stage—but once again, it's Merck & Co. stealing the spotlight.